KALA BIO Management
Management criteria checks 3/4
KALA BIO's CEO is Mark Iwicki, appointed in Sep 2015, has a tenure of 8.67 years. total yearly compensation is $1.87M, comprised of 36.5% salary and 63.5% bonuses, including company stock and options. directly owns 0.48% of the company’s shares, worth $92.92K. The average tenure of the management team and the board of directors is 6 years and 6.7 years respectively.
Key information
Mark Iwicki
Chief executive officer
US$1.9m
Total compensation
| CEO salary percentage | 36.5% |
| CEO tenure | 8.7yrs |
| CEO ownership | 0.5% |
| Management average tenure | 6yrs |
| Board average tenure | 6.7yrs |
Recent management updates
Recent updates
Kala Pharmaceuticals to execute reverse stock split
Oct 20Kala Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Staying Patient With Kala Pharmaceuticals
Aug 29The Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Have Been Trimming Their Sales Forecasts
Aug 10
Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Jul 07Is Kala Pharmaceuticals (NASDAQ:KALA) Using Debt Sensibly?
Apr 05Kala Pharmaceuticals, Inc. (NASDAQ:KALA): When Will It Breakeven?
Mar 08What Kind Of Investors Own Most Of Kala Pharmaceuticals, Inc. (NASDAQ:KALA)?
Feb 15How Many Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Shares Did Insiders Buy, In The Last Year?
Jan 25
If You Had Bought Kala Pharmaceuticals (NASDAQ:KALA) Stock A Year Ago, You Could Pocket A 77% Gain Today
Jan 04Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Dec 23The Play On Kala Pharmaceuticals
Dec 17Is Kala Pharmaceuticals (NASDAQ:KALA) Using Too Much Debt?
Dec 14How Much Did Kala Pharmaceuticals' (NASDAQ:KALA) CEO Pocket Last Year?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$46m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$26m |
| Dec 31 2022 | US$2m | US$682k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$80m |
| Jun 30 2022 | n/a | n/a | -US$137m |
| Mar 31 2022 | n/a | n/a | -US$145m |
| Dec 31 2021 | US$3m | US$644k | -US$143m |
| Sep 30 2021 | n/a | n/a | -US$126m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$113m |
| Dec 31 2020 | US$5m | US$586k | -US$104m |
| Sep 30 2020 | n/a | n/a | -US$95m |
| Jun 30 2020 | n/a | n/a | -US$90m |
| Mar 31 2020 | n/a | n/a | -US$91m |
| Dec 31 2019 | US$3m | US$564k | -US$94m |
| Sep 30 2019 | n/a | n/a | -US$98m |
| Jun 30 2019 | n/a | n/a | -US$90m |
| Mar 31 2019 | n/a | n/a | -US$81m |
| Dec 31 2018 | US$3m | US$535k | -US$67m |
| Sep 30 2018 | n/a | n/a | -US$53m |
| Jun 30 2018 | n/a | n/a | -US$47m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | US$2m | US$501k | -US$42m |
Compensation vs Market: Mark's total compensation ($USD1.87M) is above average for companies of similar size in the US market ($USD667.63K).
Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.
CEO
Mark Iwicki (57 yo)
8.7yrs
Tenure
US$1,868,299
Compensation
Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 8.7yrs | US$1.87m | 0.48% $ 92.9k | |
| President & COO | 6.5yrs | US$1.03m | 0.17% $ 33.4k | |
| Head of R&D and Chief Medical Officer | 11.3yrs | US$993.69k | 0.20% $ 37.9k | |
| Founder & Chair of the Scientific Advisory Board | no data | no data | no data | |
| CFO & Treasurer | 10.3yrs | no data | 0.15% $ 29.4k | |
| Executive Director of Investor Relations & Corporate Communications | 2.8yrs | no data | no data | |
| Senior VP of Manufacturing & Supply Chain Management | 6.8yrs | no data | no data | |
| Chief Business Officer | 2.5yrs | no data | 0.52% $ 100.1k | |
| Chief Medical Advisor | 1.2yrs | no data | no data | |
| Senior VP & Corporate Controller | 2.1yrs | no data | no data | |
| Executive Director of Account Management | 6yrs | no data | no data | |
| Executive Director of Trade & Alternate Channels | 6yrs | no data | no data |
6.0yrs
Average Tenure
55yo
Average Age
Experienced Management: KALA's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.1yrs | US$1.87m | 0.48% $ 92.9k | |
| Founder & Chair of the Scientific Advisory Board | no data | no data | no data | |
| Board Observer | 8.1yrs | no data | no data | |
| Independent Director | 6.3yrs | US$80.15k | 0.062% $ 11.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Lead Independent Director | 6.7yrs | US$101.44k | 0.078% $ 15.0k | |
| Independent Director | 2.5yrs | US$66.24k | 0.23% $ 43.9k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.6yrs | US$72.65k | 0.045% $ 8.6k | |
| Independent Director & Member of Advisory Board | 10.3yrs | US$77.65k | 0.0093% $ 1.8k |
6.7yrs
Average Tenure
65yo
Average Age
Experienced Board: KALA's board of directors are considered experienced (6.7 years average tenure).